Prosecution Insights
Last updated: October 02, 2026

Examiner: PAK, MICHAEL D

Tech Center 1600 • Art Units: 1644 1646 1654 1674 1682 1699

This examiner grants 58% of resolved cases

Performance Statistics

58.3%
Allow Rate
-1.7% vs TC avg
735
Total Applications
+30.4%
Interview Lift
1363
Avg Prosecution Days
Based on 708 resolved cases, 2023–2026

Rejection Statute Breakdown

7.8%
§101 Eligibility
21.4%
§102 Novelty
22.0%
§103 Obviousness
36.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19363223 ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY Final Rejection MORPHOSYS GMBH
15034531 COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME Non-Final OA Regeneron Pharmaceuticals, Inc.
18698912 Loading of Extracellular Signaling Molecules Into Lipid-Bound Vesicles for Therapeutic Applications Non-Final OA Carnegie Mellon University
17410658 THE FGF19-CHOLESTYRAMINE (F-CME) TEST AS A TWO-STAGE METHOD FOR ROUTINE CANCER SCREENING Final Rejection UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
18006997 NITRO COMPOUND DETECTION ELEMENT Non-Final OA SUMITOMO CHEMICAL COMPANY, LIMITED
18034289 ANTIGEN BINDING MOLECULES AND USES THEREOF Non-Final OA Agency for Science, Technology and Research
18048946 TOOLS AND METHODS FOR EXPRESSION OF MEMBRANE PROTEINS Non-Final OA Universiteit Gent

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month